

Call with Antibody Analytics

Who: Amy, Eleonora, James

Description:

- Introductions
- Take mainly protein based drugs and test them for release. Copies of antibody groups tested against antibody receptors, stability, antigen binding.
- If you're modifying the CH3 domain it's not hugely active. Useful thermostability - no need for refrigeration. New Orleans - Katrina - no power for a month - some of the drugs were fine but most wouldn't be.
- Commercial use - increase shelf life
- Any industry interest - none - most RND departments for biotech firms have to show milestones - usually can hit a target and apply it to disease - won't spend too much time polishing - a lot of stuff just gets pushed through without been polished. For project if you could show a very simple method and effect it could move away from polishing. Lala's antibodies are good examples. Lala PG if pharma companies want to sign for something.
- Want to show it has an effect - e.g. 5-10 degree stability. Then you move away from polishing. Thermal folding testing - can show you can have better refolding that's great commercially.
- Domain that would have better stability
- Don't touch variable domain -
- one antibody doesn't bind to just one antigen
- johnny sunnis - ex phaser - PDL1 drug for skin legions - can screen antibody against selection of antigens -
- CH2 would be the one you would want to try to hit - not too close to sistine bonds - look at FAB2 fragments - decreasing CSC receptor function - more side-effects
- Put the isopeptide bond near ____ = protein that has a better half life and a better chance of binding to the antigen
- Look at the process
- Testing against all human antigens - SPR - have a purified protein etc capture and see the binding response
- also can use FAX - label , put against cells that express it on surface, can engineer cell to shuttle it out
- Check you're not hitting anything off target - EPARS - public assessment record - screen test - outline of pharma companies do
- Test against human and then against another species - show its not cross species reactive - I
- L17A
- Expect to see no cross creativity if you have a mono target - if there is reactivity you have to republish
- If you make an antibody and purify it - let him know - he would be interested in testing it